CRL
NYSECharles River Laboratories International Inc.
News · 26 weeks78+467%
2026-03-012026-08-23
Mix4390d
- Insider29(67%)
- Other7(16%)
- Analyst4(9%)
- SEC Filings2(5%)
- Earnings1(2%)
Latest news
25 items- INSIDERChief Executive Officer Girshick Birgit gifted 528 shares, decreasing direct ownership by 1% to 35,485 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERCEVP, Disc & Safety Assessment Parisotto Shannon M exercised 2,039 shares at a strike of $194.12 and sold $599,711 worth of shares (2,039 units at $294.12) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERDirector Andrews Nancy C exercised 573 shares at a strike of $164.30 and sold $163,443 worth of shares (573 units at $285.24) (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- PRCharles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation SequencingCollaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testing Charles River Laboratories International, Inc. (NYSE:CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent enterovirus vaccine. The collaboration reflects both companies' shared commit
- INSIDERChief Executive Officer Girshick Birgit exercised 6,500 shares at a strike of $179.66 and sold $1,819,350 worth of shares (6,500 units at $279.90) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERCEVP, Disc & Safety Assessment Parisotto Shannon M exercised 3,714 shares at a strike of $179.66 and sold $1,038,657 worth of shares (3,714 units at $279.66) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Charles River Laboratories International Inc.SCHEDULE 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
- INSIDEREVP, Corp Strategy & Develop Laplume Joseph W gifted 257 shares, decreasing direct ownership by 0.82% to 31,041 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERDirector Foster James C exercised 28,733 shares at a strike of $179.66 and sold $7,901,575 worth of shares (28,733 units at $275.00) as part of a pre-agreed trading plan (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERSVP, Finance and CAO Knell Michael Gunnar sold $1,730,250 worth of shares (6,645 units at $260.38) and exercised 2,345 shares at a strike of $196.12, decreasing direct ownership by 27% to 11,852 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDEREVP & Chief People Officer Creamer Victoria L sold $1,083,030 worth of shares (4,179 units at $259.16) and exercised 4,179 shares at a strike of $179.66 (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERCEVP, Disc & Safety Assessment Parisotto Shannon M sold $1,327,098 worth of shares (5,046 units at $263.00) as part of a pre-agreed trading plan, decreasing direct ownership by 51% to 4,807 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
- ANALYSTCharles River upgraded by Analyst with a new price targetAnalyst upgraded Charles River from Neutral to Overweight and set a new price target of $310.00
- SECSEC Form 10-Q filed by Charles River Laboratories International Inc.10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
- SECCharles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
- PRCharles River Laboratories Announces Second-Quarter 2026 ResultsCharles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter ended June 27, 2026. Key Highlights Reports second-quarter revenue of $1.00 billion, GAAP loss per share of $(0.03), and non-GAAP earnings per share of $3.02. Organic revenue growth of 0.1% reached the highest level since the third quarter of 2023. Non-GAAP operating margin increased 420 basis points on a sequential basis to 20.5%, while the GAAP operating margin was essentially flat on a sequential basis at 11.9%. Increases 2026 guidance for revenue and non-GAAP earnings per share. Organic revenue guidance increasing by 150 basis points and non-GAAP earnings per sha
- ANALYSTCharles River downgraded by CLSA with a new price targetCLSA downgraded Charles River from Outperform to Hold and set a new price target of $219.00
- PRCharles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference CallCharles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce
- PRCharles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment ApproachesCollaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods Charles River Laboratories International, Inc. (NYSE:CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks that produc
- INSIDERDirector Foster James C sold $16,875,000 worth of shares (75,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 31,596 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- PRCharles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing ExpertiseCollaboration supports Charles River's strategic goals to build deeper client relationships to further modernize R&D through innovative technologies Charles River Laboratories International, Inc. (NYSE:CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidl
- ANALYSTCharles River upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Charles River from Equal-Weight to Overweight and set a new price target of $220.00
- INSIDERDirector Foster James C gifted 183,361 shares and received a gift of 183,361 shares, decreasing direct ownership by 62% to 106,596 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
- INSIDERChief Executive Officer Girshick Birgit gifted 3,386 shares and received a gift of 3,386 shares, decreasing direct ownership by 9% to 36,013 units (SEC Form 4)4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
CRL FAQ
7 questionsWhat does Charles River Laboratories International Inc. do?
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of...Where does CRL stock trade?
Charles River Laboratories International Inc. (CRL) is listed on NYSE.What sector and industry is CRL in?
Charles River Laboratories International Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did Charles River Laboratories International Inc. go public?
Charles River Laboratories International Inc. (CRL) completed its IPO in 2000.What are analysts saying about CRL?
Charles River Laboratories International Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight on 2026-08-06.What companies are similar to CRL?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), MEDP (Medpace Holdings Inc.), PPD (PPD, Inc.), ICLR (ICON plc). Compare CRL side-by-side with any of them on Quantisnow.How can I track CRL on Quantisnow?
Quantisnow aggregates Charles River Laboratories International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRL to receive live email and push alerts on every new disclosure.